Randomized, Controlled, Phase 2 Trial of Povidone-Iodine/Dexamethasone Ophthalmic Suspension for Treatment of Adenoviral Conjunctivitis

Abstract

PVP-I/dexamethasone appeared safe and well tolerated, and significantly improved clinical resolution and adenoviral eradication in patients with acute adenoviral conjunctivitis.

In vitro antimicrobial activity of a new ophthalmic solution containing povidone‐iodine 0.6% (IODIM®)

“…More recently, Pepose et al. () have shown that PVP‐I 0.6%/dexamethasone 0.1% appeared safe and well tolerated and significantly improved clinical resolution and adenoviral eradication in patients with acute adenoviral conjunctivitis. Furthermore, Musumeci et al.…”

<p>A Review of the Differential Diagnosis of Acute Infectious Conjunctivitis: Implications for Treatment and Management</p>

“…1 An ophthalmic suspension composed of PVP-I 0.6% and the corticosteroid dexamethasone 0.1% (PVP-I 0.6%/DEX 0.1%) has been evaluated in a Phase 2 trial. 26 Results from this study showed that PVP-I 0.6%/DEX 0.1% treatment of patients with acute adenoviral conjunctivitis significantly improved clinical resolution and eradication of adenovirus in the study eye. 26 Another compound, N-chlorotaurine, has broad-spectrum microbicidal activity due to its nonspecific reaction mechanism, and was investigated for the treatment of viral conjunctivitis.…”

“…26 Results from this study showed that PVP-I 0.6%/DEX 0.1% treatment of patients with acute adenoviral conjunctivitis significantly improved clinical resolution and eradication of adenovirus in the study eye. 26 Another compound, N-chlorotaurine, has broad-spectrum microbicidal activity due to its nonspecific reaction mechanism, and was investigated for the treatment of viral conjunctivitis. 27 A 1% solution of N-chlorotaurine was well tolerated in patients with EKC and shortened the course of disease compared with gentamicin eye drops in a randomized phase 2b study.…”

“…Development of novel agents with broadspectrum antimicrobial activity may offer potential new approaches without the drawback of resistance. 26,27,45 Medical, Ocular Therapeutix, Quidel, Shire (a Takeda company), Science Based Health, Sight Sciences, Sun, Tear Solutions, Tear Restore, and TissueTech. The authors report no other conflicts of interest in this work.…”

COVID-19: Ophthalmic prophylactic and therapeutic measures

“…Few well-designed studies have established the efficacy of Betadine eye drops in viral conjunctivitis. [ 5 ] For a case of conjunctivitis with COVID-19, this preparation may help to reduce the viral load due to its action against a wide range of viruses. Burning and irritation is a significant side effect of the drug, which can be effectively reduced by diluting 1 mL of 5% Betadine with 4 mL of BAK containing lubricant drops.…”